Mankind Pharma Ltd banner
M

Mankind Pharma Ltd
NSE:MANKIND

Watchlist Manager
Mankind Pharma Ltd
NSE:MANKIND
Watchlist
Price: 2 403.8 INR -0.09% Market Closed
Market Cap: ₹992.6B

Wall St Price Targets

MANKIND Price Targets Summary
Mankind Pharma Ltd

Wall Street analysts forecast MANKIND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MANKIND is 2 716.03 INR with a low forecast of 2 009.9 INR and a high forecast of 3 255 INR.

Lowest Forecast
Price Target
2 009.9 INR
16% Downside
Average Forecast
Price Target
2 716.03 INR
13% Upside
Highest Forecast
Price Target
3 255 INR
35% Upside
Mankind Pharma Ltd Competitors:
Price Targets

Revenue
Forecast

18% / Year
Past Growth
13% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
18% / Year
Past Growth
13% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 4 years, the compound annual growth rate for Revenue has been 18%. The projected CAGR for the next 4 years is 13%.

Gross Profit
Forecast

18% / Year
Past Growth
14% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
18% / Year
Past Growth
14% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 4 years, the compound annual growth rate for Gross Profit has been 18%. The projected CAGR for the next 4 years is 14%.

Operating Income
Forecast

12% / Year
Past Growth
16% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
12% / Year
Past Growth
16% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 4 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 4 years is 16%.

Pre-Tax Income
Forecast

10% / Year
Past Growth
15% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
10% / Year
Past Growth
15% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 4 years, the compound annual growth rate for Pre-Tax Income has been 10%. The projected CAGR for the next 3 years is 15%.

Net Income
Forecast

12% / Year
Past Growth
14% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
12% / Year
Past Growth
14% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 4 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 4 years is 14%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is MANKIND's stock price target?
Price Target
2 716.03 INR

According to Wall Street analysts, the average 1-year price target for MANKIND is 2 716.03 INR with a low forecast of 2 009.9 INR and a high forecast of 3 255 INR.

What is the Revenue forecast for Mankind Pharma Ltd?
Projected CAGR
13%

Over the last 4 years, the compound annual growth rate for Revenue has been 18%. The projected CAGR for the next 4 years is 13%.

What is the Gross Profit forecast for Mankind Pharma Ltd?
Projected CAGR
14%

Over the last 4 years, the compound annual growth rate for Gross Profit has been 18%. The projected CAGR for the next 4 years is 14%.

What is the Operating Income forecast for Mankind Pharma Ltd?
Projected CAGR
16%

Over the last 4 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 4 years is 16%.

What is the Pre-Tax Income forecast for Mankind Pharma Ltd?
Projected CAGR
15%

Over the last 4 years, the compound annual growth rate for Pre-Tax Income has been 10%. The projected CAGR for the next 3 years is 15%.

What is the Net Income forecast for Mankind Pharma Ltd?
Projected CAGR
14%

Over the last 4 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 4 years is 14%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett